Molecular aspects of high-level resistance to sulbactam-cefoperazone in Klebsiella oxytoca clinical isolates.
Nine Klebsiella oxytoca strains which demonstrated resistance to the combination of sulbactam and cefoperazone were isolated from geographically separate hospitals in Japan in 1995. Among them, K. oxytoca SB23 showed high-level resistance to sulbactam-cefoperazone (MIC > 128 micrograms/ml) and aztreonam (MIC, 128 micrograms/ml). The sulbactam-cefoperazone resistance was not transferred from strain SB23 to Escherichia coli CSH2 by conjugation, beta-Lactamase RbiA, produced by strain SB23, was purified, and the molecular mass was estimated to be 29 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Kinetic parameters for RbiA revealed that cefoperazone and aztreonam were hydrolyzed efficiently by this enzyme. Moreover, ceftazidime and imipenem were also hydrolyzed weakly by RbiA, although strain SB23 did not show any resistance to these agents. Clavulanate, sulbactam, and tazobactam failed to block the hydrolysis of cefoperazone by RbiA. The structural gene of RbiA (blaRBI) was cloned and sequenced, and the deduced amino acid sequence of RbiA demonstrated high-level similarities to those of the beta-lactamases found in K. oxytoca D488, E23004, and plasmid-mediated MEN-1, which have been classified into Bush functional group 2be. Although RbiA demonstrates high-level molecular similarity to the enzymes in group 2be, from an enzymological point of view, this enzyme might be differentiated from the enzymes in that group. Hybridization analysis revealed that beta-lactamase genes highly similar to blaRBI were generally encoded on the chromosome of the sulbactam-cefoperazone-resistant clinical isolates of K. oxytoca tested in the study, despite their different derivations. This observation suggests that sulbactam-cefoperazone-resistant A. oxytoca strains which produce RbiA-type beta-lactamases have been proliferating in many hospitals in Japan.
Kimura
K
K
Department of Bacteriology, Nagoya University School of Medicine, Japan.
Arakawa
Y
Y
Ohsuka
S
S
Ito
H
H
Suzuki
K
K
Kurokawa
H
H
Kato
N
N
Ohta
M
M
D000595:Amino Acid Sequence; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001435:Bacteriophages / Q000235:genetics; D001483:Base Sequence; D015139:Blotting, Southern; D002438:Cefoperazone / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D003001:Cloning, Molecular; D003470:Culture Media; D016208:Databases, Factual; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D007202:Indicators and Reagents; D007709:Klebsiella / Q000187:drug effects* / Q000235:genetics; D007710:Klebsiella Infections / Q000382:microbiology*; D008969:Molecular Sequence Data; D008970:Molecular Weight; D009693:Nucleic Acid Hybridization; D010957:Plasmids; D013407:Sulbactam / Q000494:pharmacology; D001618:beta-Lactamases / Q000235:genetics / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D003470:Culture Media; D007202:Indicators and Reagents; D002438:Cefoperazone; D001618:beta-Lactamases; D013407:Sulbactam